Throughout this challenging time of the COVID-19 pandemic, Glooko, a leading diabetes software company that enables people with diabetes and clinicians to manage care in real-time, is committed to helping ensure the health and well-being of people with diabetes, their caregivers, and their healthcare professionals.  Glooko is therefore taking action to serve the global diabetes community by providing a no-charge remote-care solution that provides live patient-to-clinician connectivity.

As many efforts undertaken in our communities are aimed at reducing the chances of being exposed to and spreading COVID-19, individuals who have chronic conditions like diabetes and contract the virus appear to be at a higher risk for developing complications; as such limiting exposure is critical. For certain appointments, healthcare professionals may determine that the patient and their care team would be best served by a remote review of the patient's personal diabetes data and a corresponding telehealth consult, reserving in-office visits only for those appointments where a patient's medical status truly requires in-person treatment.

To minimize the risk to people with diabetes during this time by broadening access to remote medical appointments with healthcare providers, Glooko is offering its secure, privacy-protected remote-care solution at no charge to medical clinics and people with diabetes as a public service until the greatest threat of the pandemic has subsided.

This public service is being made available to medical clinics and people with diabetes in countries where Glooko technology is already provided. 

About Glooko

Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend^® by Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world's leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.